Tanios Bekaii-Saab, MD, FACP

Tanios S. Bekaii-Saab, MD, FACP, discusses the patient population, methods, and design utilized in the phase 3 MOUNTAINEER-03 study.

Tanios Bekaii-Saab, MD, FACP, discusses background that led to the start of the MOUNTAINEER-03 trial.

Tanios S. Bekaii-Saab, MD, FACP, discusses what to expect if data from the MOUNTAINEER-03 study are positive.

Tanios S. Bekaii-Saab, MD, FACP, discusses the evolution of treatment options prior to adagrasib for patients with KRAS G12C mutations.

Tanios S. Bekaii-Saab, MD, FACP, discusses the differences between adagrasib and other KRAS inhibitors.

Tanios S. Bekaii-Saab, MD, FACP, discusses the phase 1/1b and 2 KRYSTAL-1 trial and his presentation from the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.